Home › NDC Lookup › RxCUI directory › RxCUI 2056700

1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] — RxCUI 2056700

RxNorm drug concept · Semantic branded drug
RxCUI 2056700 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2056700
Official name1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as1.5 ML Ajovy 150 MG/ML Prefilled Syringe; AJOVY 225 MG in 1.5 mL Prefilled Syringe; Ajovy 225 MG per 1.5 ML Prefilled Syringe
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)205,598 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fremanezumab-vfrm Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ajovy is strictly a preventive medication, not a rescue treatment. You take it on a regular schedule — monthly or quarterly — to reduce how often migraines happen. If you get a mig...
  • What exactly does Ajovy do — does it stop a migraine or prevent one?
  • Most adults and teens 13 and older can self-inject at home after being trained by their healthcare provider. Your doctor or pharmacist will walk you through the proper technique, i...
  • Can I give myself the injection at home, or do I need to go to a clinic?
📖 Read our full Fremanezumab-vfrm Injection guide →

🕸️ Concept Web — How 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syr... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] RxCUI 2056700

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Fremanezumab 2056691
    • Fremanezumab-vfrm 2056690
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ajovy 2056696
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fremanezumab Prefilled Syringe 2056694
    • Fremanezumab-vfrm Prefilled Syringe 2648981
    • Fremanezumab Injectable Product 2056693
    • Fremanezumab-vfrm Injectable Product 2662256
    • Fremanezumab Prefilled Syringe [Ajovy] 2056698
    • Fremanezumab-vfrm Prefilled Syringe [Ajovy] 2658446
    • Ajovy Injectable Product 2056699
    • Prefilled Syringe 721656
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe SCD · 2056695
  • Fremanezumab-vfrm 150 MG/ML SCDC · 2056692
  • Fremanezumab Prefilled Syringe SCDF · 2056694
  • Fremanezumab-vfrm Prefilled Syringe SCDFP · 2648981
  • Fremanezumab Injectable Product SCDG · 2056693
  • Fremanezumab-vfrm Injectable Product SCDGP · 2662256

Brand-Name Concepts

  • Fremanezumab-vfrm 150 MG/ML [Ajovy] SBDC · 2056697
  • Fremanezumab Prefilled Syringe [Ajovy] SBDF · 2056698
  • Fremanezumab-vfrm Prefilled Syringe [Ajovy] SBDFP · 2658446
  • Ajovy Injectable Product SBDG · 2056699
  • Ajovy BN · 2056696

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2056700 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51759-0202-10 1 CONTAINER in 1 CARTON (51759-202-10) / 1.5 mL in 1 CONTAI... AJOVY Teva Pharmaceuticals USA, Inc. 2020-03-29
51759-0202-11 1 CONTAINER in 1 CARTON (51759-202-11) / 1.5 mL in 1 CONTAI... AJOVY Teva Pharmaceuticals USA, Inc. 2020-03-29
51759-0202-22 3 CONTAINER in 1 CARTON (51759-202-22) / 1.5 mL in 1 CONTAI... AJOVY Teva Pharmaceuticals USA, Inc. 2020-08-31
51759-0204-10 1 SYRINGE, GLASS in 1 CARTON (51759-204-10) / 1.5 mL in 1 S... AJOVY Teva Pharmaceuticals USA, Inc. 2018-09-15
Observed labelers: Teva Pharmaceuticals USA, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$508.5570
Range $508.3240–$508.6070 · middle 50% $508.4405–$508.5820 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.